<?xml version="1.0" encoding="UTF-8"?>
<p id="Par51">Exclusion criteria included prior systemic chemotherapy for lung cancer; previous radiation therapy to &gt; 30% of active bone marrow or any radiation therapy within 3 weeks of Day 1; central nervous system metastases; uncontrolled hypertension; peripheral neuropathy ≥Grade 2; fever &gt; 38.5 °C within 3 days of Day 1; active yeast infection; human immunodeficiency virus/acquired immune deficiency syndrome, hepatitis B, or hepatitis C; connective tissue or autoimmune disease; previous organ or progenitor/stem cell transplant; history of myocardial infarction or any other unstable, uncontrolled heart disease; second malignancy within the previous 5 years (other than basal cell carcinoma, cervical intra-epithelial neoplasm, or curatively treated prostate cancer); known hypersensitivity to baker's yeast, murine proteins, or polyoxyethylated castor oil (Cremophor® EL); previous exposure to bevacizumab or BTH1677; or investigational therapy within 30 days prior to Day 1. Female patients were excluded if they were pregnant or breastfeeding.</p>
